This site is intended for healthcare professionals

Sign in

Direct-acting oral anticoagulants (DOACs): bleeding risk and reversal agents

Posted 10 Sept 2020

Dr Julie Oliver

Dr Julie Oliver discusses this topic in the context of a recent update from the Medicines and Healthcare products Regulatory Agency (MHRA).

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.